One Asset Deal Changed Everything For Tianjin Da Ren Tang In Q3 2025
This financial report captures a pivotal moment for the Group, marked by major changes in business scope and strategic divestments. The performance reflects a significant non-operating boost from the sale of a key equity interest. While facing external pressures, particularly within the upstream supply chain of the Traditional Chinese Medicine (TCM) industry, the Group is moving forward by deepening its brand-led strategy and investing heavily in research and development. • Discover the exceptional transaction that delivered a substantial non-operating gain to the Group’s bottom line during…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.